Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Parihar

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Communications Biology|March 20, 2021
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumorsAmanda Rosewell Shaw, Caroline E Porter, Tiffany Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.
The Journal of Clinical Investigation|July 17, 2003
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouseGregory B Lesinski, Mirela Anghelina, Jason Zimmerer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patientsRobin Parihar, Padma Nadella, Adrian Lewis, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.
Frontiers in Medicine|January 9, 2019
Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T CellsBilal Omer, Paul A Castillo, Haruko Tashiro, et al.
BMC Medical Genomics|October 17, 2015
Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12Amanda R Campbell, Kelly Regan, Neela Bhave, et al.
Oncoimmunology|October 6, 2018
TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapyPadmini Jayaraman, Falguni Parikh, Jared M Newton, et al.
Cancer Discovery|August 24, 2017
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T CellsThomas Shum, Bilal Omer, Haruko Tashiro, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Communications Biology|March 20, 2021
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumorsAmanda Rosewell Shaw, Caroline E Porter, Tiffany Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.
The Journal of Clinical Investigation|July 17, 2003
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouseGregory B Lesinski, Mirela Anghelina, Jason Zimmerer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patientsRobin Parihar, Padma Nadella, Adrian Lewis, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.
Frontiers in Medicine|January 9, 2019
Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T CellsBilal Omer, Paul A Castillo, Haruko Tashiro, et al.
BMC Medical Genomics|October 17, 2015
Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12Amanda R Campbell, Kelly Regan, Neela Bhave, et al.
Oncoimmunology|October 6, 2018
TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapyPadmini Jayaraman, Falguni Parikh, Jared M Newton, et al.
Cancer Discovery|August 24, 2017
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T CellsThomas Shum, Bilal Omer, Haruko Tashiro, et al.
Pageof 4